non injectable semaglutide Oral Shows Promise in Adolescents with Type 2 Diabetes Oral GLP-1 Medication Helps Patients

There is always a risk of injury from the actual injection, but that isnt necessarily the manufacturers fault

What is LEILA Return Policy

This widespread use of these popular weight loss drugs, both for approved diabetes treatment and off-label weight loss, has now resulted in thousands of patients reporting severe gastrointestinal injuries and vision loss, conditions that many allege were not adequately disclosed on warning labels when they began treatment

Results The proportions of patients who discontinued study drug in Studies 2, 3, and 4 was 16.0% for the WEGOVY-treated group and 19.1% for the placebo-treated group, and 6.8% of patients treated with WEGOVY and 3.2% of patients treated with placebo discontinued treatment due to an adverse reaction [see Adverse Reactions (6.1)]